Table 2 Baseline characteristics at treatment initiation
Parameters | Variables | Total number | Percentages |
|---|---|---|---|
Total number | 50 | ||
Age (years), median (range) | 58 (27–87) | ||
≥ 65 years | 14 | 28% | |
Sex | |||
male | 31 | 62% | |
female | 19 | 38% | |
ECOG PS | |||
0 | 6 | 12% | |
1 | 20 | 40% | |
≥ 2 | 12 | 24% | |
unknown | 12 | 24% | |
Primary tumour localisation | |||
Gastric | 27 | 54% | |
Gastroesophageal junction | 23 | 46% | |
Resection of primary tumour | |||
yes | 25 | 50% | |
no | 25 | 50% | |
Perioperative therapy | |||
yes | 24 | 48% | |
no | 26 | 52% | |
Number of previous palliative therapy lines | |||
0 | 7 | 14% | |
1 | 10 | 20% | |
2 | 19 | 38% | |
≥ 3 | 14 | 28% | |
Number of subsequent palliative therapy lines | |||
0 | 37 | 74% | |
1 | 7 | 14% | |
≥ 2 | 6 | 12% | |
Time point of metastases detection | |||
synchronous | 25 | 50% | |
metachronous | 25 | 50% | |
Site of metastases 1 | Peritoneum | 17 | 34% |
Lung | 11 | 22% | |
Liver | 25 | 50% | |
Other | 39 | 78% | |
Histologic subtype (Lauren classification) | |||
intestinal | 21 | 42% | |
diffuse or signet ring cell | 12 | 24% | |
unspecified | 17 | 34% | |
HER-2 status | |||
positive | 8 | 16% | |
negative | 40 | 80% | |
unknown/missing | 2 | 4% | |
Microsatellite status | |||
MSI | 8 | 16% | |
MSS | 31 | 62% | |
unknown/missing | 11 | 22% | |
PD-L1 expression | |||
positive (CPS ≥1 or TPS ≥1%) | 24 | 48% | |
negative | 13 | 26% | |
unknown/missing | 13 | 26% | |